FiercePharmaOriginal article
{"a":[{"_":"Novo, Alvotech face continued FDA scrutiny at plants tied to recent FDA rejections","$":{"href":"/pharma/novo-alvotech-face-continued-fda-scrutiny-plants-tied-recent-fda-rejections","hreflang":"en"}}]}
RegulatoryNegative
AI Analysis
Summary
Novo and Alvotech face continued FDA scrutiny at manufacturing plants in Indiana and Iceland following recent FDA rejections. The FDA disclosed concerns raised during recent facility visits to sites with troubled regulatory histories.
Outcome Details
FDA disclosed concerns raised during recent visits to manufacturing sites with troubled regulatory histories; sites located in Indiana and Iceland
Importance:6/10
Sentiment:
-0.70
FDA inspectionmanufacturing concernsregulatory scrutinycompliance
Related Companies
Read the original article
Published by FiercePharma on July 17, 2026 10:36 AM